 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q4 2023 Affimed NV Earnings Call Transcript

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete...

Affimed Reports 2023 Financial Results and Operational Progress

Affimed (NASDAQ:AFMD) va annoncer ses derniers b n fices ce jeudi. Suivez les tendances du march , avec l'aper u des b n fices du quatri me trimestre de Affimed de Benzinga.
R sultat net, b n fices...

Aper u : B n fices de Affimed

MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) ( Affimed or the Company ), a clinical-stage immuno-oncology company committed to giving patients back their...

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) ( Affimed or the Company ), a clinical-stage immuno-oncology company committed to giving patients back their...

Affimed Announces 1-for-10 Reverse Stock Split

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows three...

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go...

Affimed Announces Leadership Change and Organizational Restructuring

MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) ( Affimed or the Company ), a clinical-stage immuno-oncology company committed to giving patients back their...

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

Volume (M)	3,444.00
52-Wk High	$11.10
52-Wk Low	$2.24

AFMD Affimed N.V.

About

Feed

News

Sentiment

Earnings

Fundamentals